Enhancing activity of CAR T cells by co-introducing a bispecific antibody

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10696749
APP PUB NO 20180057609A1
SERIAL NO

15690383

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA3600 CIVIC CENTER BOULEVARD 9TH FLOOR PHILADELPHIA PA 19104

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
June, Carl H Merion Station, US 193 6626
Liu, Xiaojun Wallingford, US 91 326
Zhao, Yangbing Lumberton, US 53 621

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 30, 2023
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00